IN8BIO, INC. — Investor Relations & Filings
IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform utilizes allogeneic, autologous, and genetically modified approaches to develop novel cell therapies. IN8BIO was the first to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400, a Phase 2 asset for newly diagnosed glioblastoma (GBM), and INB-100, a Phase 1 candidate for patients with leukemia undergoing hematopoietic stem cell transplantation. The company is also advancing a broad portfolio of preclinical programs focused on solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 424B3 Filing | 2026-01-30 | English | |
| S-3 | 2026-01-20 | English | |
| Major Shareholding Notification 2026 | 2026-01-02 | English | |
| Regulatory Filings 2025 | 2025-12-30 | English | |
| Major Shareholding Notification 2025 | 2025-12-30 | English | |
| Major Shareholding Notification 2025 | 2025-12-29 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
3 filings
| |||||
| 31546663 | 424B3 Filing | 2026-01-30 | English | ||
| 13111115 | S-3 | 2026-01-20 | English | ||
| 13111116 | Major Shareholding Notification 2026 | 2026-01-02 | English | ||
|
2025
12 filings
| |||||
| 13111117 | Regulatory Filings 2025 | 2025-12-30 | English | ||
| 13111118 | Major Shareholding Notification 2025 | 2025-12-30 | English | ||
| 13111119 | Major Shareholding Notification 2025 | 2025-12-29 | English | ||
| 13111120 | Director's Dealing 2025 | 2025-12-24 | English | ||
| 13111121 | Director's Dealing 2025 | 2025-12-24 | English | ||
| 13111122 | Director's Dealing 2025 | 2025-12-24 | English | ||
| 13111123 | Director's Dealing 2025 | 2025-12-24 | English | ||
| 13111124 | Director's Dealing 2025 | 2025-12-24 | English | ||
| 13111125 | Director's Dealing 2025 | 2025-12-24 | English | ||
| 13111126 | Major Shareholding Notification 2025 | 2025-12-22 | English | ||
| 13111127 | 8-K | 2025-12-19 | English | ||
| 13111128 | 8-K | 2025-11-24 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
IN8BIO, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35200/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35200 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35200 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35200 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35200}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for IN8BIO, INC. (id: 35200)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.